[Form 4] PROCEPT BioRobotics Corp Insider Trading Activity

Rhea-AI Filing Summary

PROCEPT BioRobotics Corp executive sells small number of shares for tax withholding. EVP and Chief Legal Officer Nouri Alaleh sold 285 shares of common stock at an average price of $28.48 per share in an open‑market transaction.

According to the footnote, this sale was executed under the company’s sell‑to‑cover process to satisfy tax obligations related to restricted stock units that vested on June 5, 2026. After the transaction, Alaleh directly holds 105,069 shares of PROCEPT BioRobotics common stock, so the sale represents a very small portion of his overall holdings.

Insights

Equity compensation and insider-trading analyst

Small, tax-driven sale tied to RSU vesting; routine and low signal.

The filing shows EVP and Chief Legal Officer Nouri Alaleh sold 285 shares of PROCEPT BioRobotics common stock at $28.48 per share. A footnote explains this was part of the issuer’s sell‑to‑cover process for tax withholding on restricted stock units that vested on June 5, 2026.

Sell‑to‑cover transactions occur automatically to pay taxes when equity awards vest and generally do not reflect a discretionary view on the stock. After this sale, Alaleh still owns 105,069 shares, so the transaction is very small relative to his total position and appears routine.

Insider Trade Summary

Net Seller: 285 shares ($8,117)

Net Sell 1 txn

Insider Nouri Alaleh

Role EVP, CLO, CORP. SEC.

Sold 285 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Common Stock	285	$28.479	$8K

Holdings After Transaction: Common Stock — 105,069 shares (Direct, null)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nouri Alaleh

(Last) (First) (Middle)

C/O PROCEPT BIOROBOTICS CORPORATION

150 BAYTECH DRIVE

(Street)

SAN JOSE CALIFORNIA 95134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO, CORP. SEC.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/08/2026		S		285(1)	D	$28.479	105,069	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person pursuant to the Issuer's sell-to-cover process for tax withholding obligations in connection with the vesting of the Restricted Stock Units on June 5, 2026.

Remarks:

	/s/ Jonathan Stone, Attorney-in-Fact for Alaleh Nouri	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)